People with chronic kidney disease often struggle to balance fluids and salts. This trial looked at what happens when they take a specific combination of diuretics called amiloride and hydrochlorothiazide. The study involved 26 participants with an average kidney function level of 39. Some of these individuals had low sodium levels, a condition known as hyponatremia, while others had stable sodium levels.
The medication caused noticeable changes in the blood and urine. Plasma glutamine levels dropped. The body also excreted fewer metabolites related to the tricarboxylic acid cycle, which is a key process for energy production. At the same time, urinary ammonium excretion went up. In the four patients with hyponatremia, researchers observed a specific signature of oxidative stress in their urine.
Safety was a concern because the drug caused hyponatremia in some participants. This means their sodium levels fell below 136 mmol per liter. The study only lasted two weeks, so we do not know if these chemical changes last longer or if they lead to better health outcomes. The small group size also limits what we can conclude about this treatment for everyone.